Jimmy Ren

Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

W. Timothy Garvey, Luc Van Gaal, Lawrence A. Leiter et al. · Metabolism · 2018 · 268 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

Michael Pfeifer, Raymond R. Townsend, Michael J. Davies et al. · Cardiovascular Diabetology · 2017 · 142 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Design and Synthesis of <i>N</i>-[(4-Methoxyphenoxy)carbonyl]-<i>N</i>-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities

Pratik Devasthale, Sean Chen, Yoon Jeon et al. · Journal of Medicinal Chemistry · 2004 · 108 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Sodium‐glucose co‐transporter ( <scp>SGLT</scp> ) and glucose transporter ( <scp>GLUT</scp> ) expression in the kidney of type 2 diabetic subjects

Luke Norton, Chris E. Shannon, Marcel Fourcaudot et al. · Diabetes Obesity and Metabolism · 2017 · 89 citations

Medicine, Endocrinology, Pharmacology +16

Reductions in Mean 24‐Hour Ambulatory Blood Pressure After 6‐Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension

Raymond R. Townsend, Israel Machin, Jimmy Ren et al. · Journal of Clinical Hypertension · 2015 · 83 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14